Why is PD-L1 expression on CTCs important for target validation?

PD-L1 expression on circulating tumor cells serves as a predictive biomarker for immune checkpoint inhibitor response in NSCLC, enabling stratification of patients likely to benefit from immunotherapy. Its detection in CTCs provides a liquid biopsy alternative to tissue-based PD-L1 testing, supporting repeated monitoring during treatment. This facilitates target validation by linking biomarker expression to functional immune evasion mechanisms in circulating tumor populations.

How does isolating CTCs without specific biomarkers support discovery pipeline goals?

Microfluidic enrichment based on size and plasticity captures CTCs regardless of EpCAM expression, enabling detection of mesenchymal and hybrid states associated with metastasis and therapy resistance. This unbiased isolation preserves biological heterogeneity critical for accurate target validation and mechanistic de-risking. By avoiding marker-dependent loss, the method improves confidence in downstream functional and molecular analyses.

What quantitative measurements does immunofluorescence enable for CTC characterization?

Immunofluorescence staining allows quantitative assessment of PD-L1 protein expression levels at the single-cell level, including intensity and percentage of positive cells within the enriched CTC population. These measurements support correlation with clinical outcomes and therapeutic response, providing a basis for biomarker threshold definition. The protocol also enables multiplexing with other markers to assess co-expression patterns and phenotypic states.

Why are replication and standardization requirements critical for CTC workflows?

Due to the low abundance and high variability of CTCs, standardized enrichment and staining protocols are essential to ensure reproducibility across runs, operators, and sample types. Consistent cytospin conditions, antibody incubation times, and imaging parameters reduce technical noise and improve confidence in comparative analyses. Standardization enables cross-functional collaboration between discovery, translational, and clinical teams by generating comparable data sets.

What statistical analysis capabilities are needed before implementing CTC PD-L1 assessment?

Implementation requires statistical tools to analyze single-cell fluorescence intensity data, including distribution analysis, threshold setting for positivity, and correlation with clinical endpoints. The method supports comparison of PD-L1+ CTC frequencies across treatment arms or time points, necessitating appropriate sample size calculations and hypothesis testing frameworks. These capabilities ensure that observed differences are biologically meaningful and not driven by technical variability in rare event detection.

Półautomatyczna charakterystyka i liczenie krążących komórek nowotworowych PD-L1 od pacjentów z niedrobnokomórkowym rakiem płuca za pomocą immunofluorescencji

10.2K wyświetleń

Cytowany 5 razy

10:29 min

14 sierpnia 2019

10.3791/59873-v

14 sierpnia 2019

10.2K wyświetleń

Jessica Garcia¹^,²^,³ , David Barthelemy¹^,²^,³ , Florence Geiguer¹^,² , Julie Ballandier¹^,²^,³ , Kathryn W. Li⁴ , Jean-Phillippe Aurel⁴ , Frédérique Le Breton⁵ , Claire Rodriguez-Lafrasse¹ , Brigitte Manship³ , Sébastien Couraud⁶^,⁷ , Léa Payen¹^,²^,³

¹Laboratoire de Biochimie et Biologie Moléculaire, Groupe Hospitalier Sud, Hospices Civils de Lyon, ²Circulating Cancer (CIRCAN) Program, Hospices Civils de Lyon Cancer Institute, ³University of Lyon, Claude Bernard University, Cancer Research Center of Lyon, ⁴Biolidics Limited, ⁵Institut de Pathologie Multisites des HCL-Site Sud, Hospices Civils de Lyon, ⁶Acute Respiratory Disease and Thoracic Oncology Department, Lyon Sud Hospital, Hospices Civils de Lyon Cancer Institute, ⁷EMR-3738 Therapeutic Targeting in Oncology, Lyon Sud Medical Faculty, Lyon 1 University

Charakterystyka krążących komórek nowotworowych (CTC) jest popularnym tematem w badaniach translacyjnych. Protokół ten opisuje półautomatyczny test immunofluorescencyjny (IF) do charakterystyki PD-L1 i liczenia CTC w próbkach pacjentów z niedrobnokomórkowym rakiem płuca (NSCLC).